d******8
发帖数: 1972 | 1 新型伟哥，据说比伟哥效果更快，明天开盘会不会大涨？还是已经涨过了。
NEW YORK - The Food and Drug Administration on Friday approved a new
impotence drug, Vivus Inc.'s Stendra.
The pill is intended to be taken 30 minutes before sex, but Vivus said that
in clinical trials, some patients were able to have sex as little as 15
minutes after taking the drug. Pfizer Inc.'s Viagra is supposed to be taken
at least 30 minutes before sex. The FDA said an estimated 30 million men
have importance, or erectile dysfunction.
In clinical trials, ... 阅读全帖 |
|
y**w
发帖数: 516 | 2 Vivus Inc.'s weight-loss pill Qnexa won the backing of a U.S. advisory panel
as the company seeks to gain approval for the first new obesity drug in 13
years. The shares doubled in late trading.
Advisers to the Food and Drug Administration voted 20-2 today that Qnexa's
benefits outweigh its risks at a meeting at agency headquarters in Silver
Spring, Maryland. The FDA isn't required to follow the panel's
recommendation. The agency is due to decide on the drug, which it rejected
in 2010, by April ... 阅读全帖 |
|
t******g
发帖数: 462 | 3 A lot of options will be dead
http://www.businessweek.com/news/2012-04-09/vivus-weight-loss-d
Vivus Inc. (VVUS) (VVUS) said U.S. regulators delayed their decision date on
whether to approve the obesity pill Qnexa by three months to July 17.
The date was extended after Vivus submitted, at the Food and Drug
Administration’s request, a risk evaluation and mitigation strategy, the
company said today in a statement. The strategy is based on discussions with
the agency after advisers voted Feb. 22 in ... 阅读全帖 |
|
d******8
发帖数: 1972 | 4 MOUNTAIN VIEW, Calif. (TheStreet) -- U.S. regulators have apparently
approved Vivus'(VVUS) weight-loss pill Qsymia on Tuesday, which means obese
Americans now have a choice in prescription diet pills.
http://www.thestreet.com/story/11620859/1/vivus-weight-loss-pil
A story touting Qsymia's approval was published prematurely by USA Today
earlier today. The story, since removed from the newspaper's web site,
quotes Vivus executives and doctors about Qsymia and its approval. Clearly,
the reporter wr... 阅读全帖 |
|
m******g
发帖数: 3253 | 5 Vi Veri Veniversum Vivus Vici" = Latin, "By the power of Truth, I, while
living, have conquered the Universe" |
|
|
w*******d
发帖数: 3714 | 7 UPDATE 1-Vivus shares fall on regulatory concerns
Tue Jun 15, 2010 3:10pm EDTStocks
* Jefferies: FDA likely to focus on cardiovascular risk
* Lazard downgrades shares to "hold" from "buy"
* Qnexa FDA panel follows Avandia panel
* Shares down 8 pct in afternoon (Adds analyst comment, company comment,
updates stock price)
By Deena Beasley
LOS ANGELES, June 15 (Reuters) - Shares of Vivus Inc (VVUS.O) fell as much
as 9 percent on Tuesday after analysts raised questions about how U.S.
regulators wil... 阅读全帖 |
|
v**********m
发帖数: 5516 | 8 Orexigen Revives Obesity Drug Development With FDA Agreement
Q
By Ryan Flinn - Sep 20, 2011 4:38 PM ET
inShare1
More
Print
Email
Orexigen Therapeutics Inc. (OREX) is renewing development of the
experimental obesity drug Contrave after reaching an agreement with U.S.
regulators to further study heart risks.
Orexigen, one of three companies with rival obesity treatments competing for
approval, will start a two-year clinical trial of about 10,000 patients in
the first half of next y... 阅读全帖 |
|
v**********m
发帖数: 5516 | 9 Orexigen Revives Obesity Drug Development With FDA Agreement
Q
By Ryan Flinn - Sep 20, 2011 4:38 PM ET
inShare1
More
Print
Email
Orexigen Therapeutics Inc. (OREX) is renewing development of the
experimental obesity drug Contrave after reaching an agreement with U.S.
regulators to further study heart risks.
Orexigen, one of three companies with rival obesity treatments competing for
approval, will start a two-year clinical trial of about 10,000 patients in
the first half of next y... 阅读全帖 |
|
N**********p
发帖数: 408 | 10 February 25th is the day that Vivus (VVUS) will offer its Q4 quarterly
conference call. There will be a lot of ears listening to the call, but many
of them will not even have an investment in Vivus. Others that will be
paying close attention are investors in Arena (ARNA) and Orexigen (OREX).
Vivus, Arena and Orexigen all are vying for a position in the prescription
anti-obesity market, and while the three companies are at different stages,
the results offered by Vivus could be telling in what to... 阅读全帖 |
|
n**********8
发帖数: 340 | 11 【 以下文字转载自 Chinook 俱乐部 】
发信人: niuniuzhu168 (妞妞), 信区: Chinook
标 题: Four Drug Stocks Facing FDA Approval Decisions in July
发信站: BBS 未名空间站 (Wed Jul 4 00:08:43 2012, 美东)
BOSTON (TheStreet) -- Four FDA drug approval decisions in July -- headlined
by another weight-loss drug and a prescription fish oil pill with
blockbuster potential -- will keep biotech investors busy in what is
normally one of the sector's slower months.
Vivus(VVUS_) is expected to learn the fate of its weight-loss pill Qnexa on
Tu... 阅读全帖 |
|
|
y*****l
发帖数: 5997 | 13 盘前到8块了？！
FDA Rejects Vivus Inc.'s Obesity Drug Qnexa
Thursday 10/28/2010 9:18 PM ET - Dow Jones News
Related Companies
Symbol Last %Chg
ARNA 1.59 0.00%
VVUS 6.13 0.00%
As of 4:00 PM ET 10/28/10
By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES
WASHINGTON (Dow Jones)--The Food and Drug Administration rejected Vivus Inc.
's (VVUS) obesity drug Qnexa, the company said Thursday.
The rejection marks the second time in less than a week that the agency has
refused to sign off on... 阅读全帖 |
|
S***a
发帖数: 1072 | 14 September's BioPharma Catalyst Calendar
By Lisa LaMotta Sep 01, 2010 2:40 pm
This month could be full of opportunities for biotech and pharmaceutical
investors who know where to look.
•More by Lisa LaMotta
•Forest Faces a Positive-Leaning PanelOrexigen Fattens Its Coffers
With Takeda CashSeptember's BioPharma Catalyst CalendarWhat's the Buzz?
30 top traders on these stocks and more
VVUS 6.33 +0.61 (+10.75%)
FRX 29.20 +1.55 (+5.61%)
CBST 22.52 -0.09 (-0.40%)
... 阅读全帖 |
|
v**********m
发帖数: 5516 | 15 楼上文章的comments
Not yet but stay tuned. But a definite fact and you can review it in the FDA
's analysis in the briefing document is that there was no SS of astrocytomas
in male rats or female rats.
Dr. Alavi had concerns about how Arena calculated the exposure margin for
Lorcaserin, that is why it appeared in the CRL. When Arena met directly with
the FDA on December 15th and 16th at the FDA, both Arena and the FDA agreed
on the CSF methodology and the number of participants that would be
acceptab... 阅读全帖 |
|
y*****l
发帖数: 5997 | 16 22 Hot Drugs Facing FDA Approval in 2012
By Adam Feuerstein 11/29/11 - 08:55 AM EST
BOSTON (TheStreet) -- Here's your first look at the biotech and
pharmaceutical companies with pending FDA drug approval decisions in 2012.
The calendar on the following pages captures nearly two-dozen U.S.
regulatory events -- FDA drug approvals and advisory panels -- expected
between December 2011 and July 2012. As every savvy biotech investor and
trader knows, the volatility in biotech and drug stocks ramps sig... 阅读全帖 |
|
l*********m
发帖数: 446 | 17 http://www.thestreet.com/story/13277174/6/5-stocks-under-10-set
"One final under-$10 biopharmaceutical player that's starting to trend
within range of triggering a big breakout trade is Vivus (VVUS) , which
develops and commercializes therapies to address unmet needs in obesity,
sleep apnea, diabetes, and sexual health in the U.S. and the European Union.
This stock has been hit hard by the bears over the last three months, with
shares down large by 50.2%.
If you take a glance at the chart for Vi... 阅读全帖 |
|
j****e
发帖数: 624 | 18
VIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity
drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and
the panel are comfortable with the cardiovascular profile of VIVUS' drug,
Qnexa. The firm indicates that it doesn't expect the agency to require
additional cardiovascular tests before Qnexa is approved, and it reiterates
an Outperform rating on VIVUS. :theflyonthewall.com
no... 阅读全帖 |
|
O**I
发帖数: 776 | 19 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
|
s**********o
发帖数: 14359 | 21 市场的报道是，市场已经PRICE IN VVUS的药已经通过，
If Vivus doesn't get the FDA approval, expect Vivus to tank and Arena to
surge. |
|
|
h*******g
发帖数: 205 | 23 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm
FDA approves weight-management drug Qsymia
The U.S. Food and Drug Administration today approved Qsymia (phentermine and
topiramate extended-release) as an addition to a reduced-calorie diet and
exercise for chronic weight management.
The drug is approved for use in adults with a body mass index (BMI) of 30 or
greater (obese) or adults with a BMI of 27 or greater (overweight) who have
at least one weight-related condition suc... 阅读全帖 |
|
p********e
发帖数: 1960 | 24 周末刚刚被某娱乐周刊评为2014的潜力股
2014 Top health-care stock No. 1: Joining the pack
It's a heck of a lot easier to determine the potential value a biotech when
there's a company further ahead with nearly identical assets. Orexigen (
NASDAQ: OREX ) has two.
The biotech is developing an obesity drug Contrave, which will be reviewed
by the FDA in 2014. Further ahead, Arena Pharmaceuticals (NASDAQ: ARNA )
developed obesity drug Belviq that launched this year. VIVUS (NASDAQ: VVUS
) sells Qsymia, which has bee... 阅读全帖 |
|
f**********g
发帖数: 2252 | 25 Vivus Inc. (VVUS) shares surged 30% to $8.01 premarket as investors see hope
in FDA's rejection letter of its diet drug Qnexa. The company will file a
response in six weeks to the agency's concerns, and a conference call may
provide more insights. Jefferies notes Vivus' bullish stance in getting the
drug approved, but remains cautious toward the stock because of the ongoing
risk. |
|
f**********g
发帖数: 2252 | 26 3rd UPDATE: FDA Panel Backs Use Of Orexigen's Proposed Weight-Loss Drug
Contrave
Tuesday 12/07/2010 7:06 PM ET - Dow Jones News
Related Companies
Symbol Last %Chg
ARNA 1.66 17.73%
OREX 10.82 127.31%
VVUS 9.00 15.38%
As of 9:35 AM ET 12/8/10
(Updates after-hours share movement)
By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES
WASHINGTON (Dow Jones)--A federal advisory panel Tuesday backed the use of a
proposed weight-loss drug from Orexigen Therapeutics Inc. (OREX), saying
potential safety conce... 阅读全帖 |
|
O**I
发帖数: 776 | 27 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 28 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
w*******0
发帖数: 13 | 29 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 30 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 31 http://www.thestreet.com/story/11016605/1/biotech-calendars-201
By Adam Feuerstein 02/22/11 - 07:36 AM ES
Stock quotes in this article:HGSI, OPTR, XNPT, SPPI, DRRX, PATH
BOSTON (TheStreet) -- I've updated the 2011 FDA drug approval calendar.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regul... 阅读全帖 |
|
w*******d
发帖数: 3714 | 32 Arena's drug, lorcaserin, works in a similar way to fenfluramine, but
appears to be safer. One trial of lorcaserin showed that patients who took
the drug twice a day for a year lost, on average, 5.9 percent of their body
weight, compared with 2.8 percent for those taking a placebo.
Vivus' drug, Qnexa, combines relatively low doses of phentermine with the
epilepsy drug topiramate, sold under the brand name Topamax. One late-stage
trial showed that patients who took Qnexa lost an average of 14.7 p |
|
w*******d
发帖数: 3714 | 33 So is Qnexa by Vivus, you know what happened |
|
f******u
发帖数: 250 | 34 明天最惨的将是: VIVUS, Inc.(NasdaqGM: VVUS) |
|
w****r
发帖数: 245 | 35 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
|
|
|
|
p********e
发帖数: 1960 | 40 Cramer said that when it comes to biotech companies, he looks for small,
undiscovered names -- the exact opposite of Arena, which took center stage
when its weight loss drug Belviq received U.S. Food and Drug Administration
approval earlier this year. While the markets are expecting Belviq to be a $
1 billion to 3 billion opportunity for the company, it may not be able to
live up to the hype.
What could go wrong? Well, for starters Belviq its not the panacea for
obesity. The drug only produces a... 阅读全帖 |
|
|
|
h*******g
发帖数: 205 | 43 同意“如果能够通过，ARNA可能会掉一些，但肯定不会出现恐慌性大跌。”
VVUS如果通过，有可能
“A severely restrictive label, such as a patient registry, would be
devastating to the outlook for Qnexa (and consequently Vivus shares)” |
|
k**********4
发帖数: 16092 | 44 here is the reason, wonder how true it is.
the USA Today appears to have jumped the gun with an article suggesting the
FDA has ok'd VIVUS's (Nasdaq: VVUS) Qnexa, which will be marketed under
Qsymia.
A new prescription diet drug OK'd today by the government is expected to
help heavy patients drop about 10% of their weight — more than any other
approved obesity medication.
The article appears to have been inadvertent posted early, as the FDA
decision has yet been announced. It was taken down at th... 阅读全帖 |
|
|
u**********n
发帖数: 8905 | 46 VIVUS PT Lowered to $6.00 (VVUS)
太狠了！腰斩都不满足 |
|
k**********4
发帖数: 16092 | 47 看来FA 还是有用的，很早以前业内人士就认为 Vivus不是什么好药,
arna is much better. |
|
g****e
发帖数: 1426 | 48 Since the last call, it went over $15.5. Then went down..
Now @12.43. It seems 11.90 is a bottom and will have lots of catalyst events
to move it up.
Next catalyst before ER:
Feb 13, 2013
Vivus Inc. at Leerink Swann Global Healthcare Conference -
12:00PM EST
Overall, I think VVUS is very bullish in 2013. Prescription scripts have
been steady up and the market is surly huge. Furthermore, large shareholders
are angry about the stock performance and threat to put the company for
sale. Remember it h... 阅读全帖 |
|
b*d
发帖数: 3069 | 49 VVUS这两天走的不错。
近期的一些events
1） 上周五欧洲CHMP建议批准它家的一个治疗ED的药，wsn们有福气了：）
2） 下周有Apr 30, 2013Vivus Inc. at Needham Healthcare Conference - 9:40AM
EDT -
3） May 6, 2013 Q1 2013 Vivus Inc. Earnings Release
不知道下面怎么走。 |
|
g****e
发帖数: 1426 | 50 Just filled:
B 2014-01-30 21:30:44 VIVUS INC VVUS BlackRock Inc 7.4%
view |
|
